Fol­low­ing the flow of the biotech in­dus­try, La­va heads to Nas­daq with a gam­ma delta T cell promise

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Join­ing in on the great IPO erup­tion of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.